New research suggests that existing FDA-approved medications may help treat lingering lung complications caused by COVID-19 by disrupting harmful immune responses.
RT’s Three Key Takeaways:
- Potential Treatment for Post-COVID Lung Damage: Researchers at the University of Virginia and Cedars-Sinai have identified arthritis drugs, including baricitinib and anakinra, as potential treatments for persistent lung complications following COVID-19.
- Immune System Malfunction: The study found that malfunctioning immune cell interactions, particularly between CD8+ T cells and macrophages, are driving inflammation and lung fibrosis even after the initial COVID-19 infection has cleared.
- Broader Implications: Researchers say the findings could not only provide new treatment options for COVID-19-related lung fibrosis but may also offer solutions for lung damage caused by other respiratory infections.
Arthritis drugs already available for prescription have the potential to halt lingering lung problems that can last months or years after COVID-19 infections, new research from the University of Virginia (UVA) School of Medicine and Cedars-Sinai suggests.
By examining damaged human lungs and developing a new lab model, the scientists identified faulty immune processes responsible for the ongoing lung issues that plague an increasing number of people after they’ve otherwise recovered from COVID-19. These lasting harms of COVID infection, known as “post-infection lung fibrosis,” have no good treatments.
The new research, however, suggests that existing drugs such as baricitinib and anakinra can disrupt the malfunctioning immune response and finally allow damaged lungs to heal.
“Our collaboration with doctors and computer biologists at UVA and Cedars-Sinai…led us to uncover the root cause of persistent lung inflammation and scarring after severe acute COVID-19 and possibly other respiratory infections like the flu,” says researcher Jie Sun, PhD, of UVA’s Carter Center for Immunology Research and UVA’s Division of Infectious Diseases and International Health, in a release.
Comparing Lung Tissues
Using advanced technologies like spatial transcriptomics and sophisticated microscopy, the researchers compared lung tissues from patients and animal models they developed in the lab. They found that malfunctioning immune cells disrupt the proper healing process in the lungs after viral damage.
“Importantly, we also identified the molecules responsible for this issue and potential therapeutic options for patients with ongoing lung damage,” Sun says in a release.
Researcher Chongzhi Zang, PhD, of UVA’s Department of Genome Sciences, explains in a release, “Spatial-omics’ are state-of-the-art technologies that can measure the molecular features with spatial location information within a sample. This work demonstrates the power of spatial transcriptomics combined with data science approaches in unraveling the molecular etiology of long COVID.”
The researchers note that the findings could prove beneficial not just for lung scarring from COVID but for lung fibrosis stemming from other sources as well.
“This study shows that treatments used for the acute COVID-19 disease may also reduce the development of chronic sequelae, including lung scarring,” says Peter Chen, MD, the Medallion Chair in Molecular Medicine and interim chair of the Department of Medicine at Cedars-Sinai, in a release. “Our work will be foundational in developing therapies for lung fibrosis caused from viruses or other conditions.”
Understanding COVID-19 Lung Damage
The researchers, led by Sun, Chen, and Zang,wanted to better understand the cellular and molecular causes of the lingering lung problems that can follow COVID infections. These problems can include ongoing lung damage and harmful inflammation that persists well after the COVID-19 virus has been cleared from the body.
The researchers began by examining severely damaged lungs from transplant patients at both UVA and Cedars-Sinai. None of the patients had a lung disease that would have required a transplant prior to contracting COVID-19, so the scientists were hopeful that the lungs would provide vital clues as to why the patients suffered such severe lung damage and persistent fibrosis. Using the insights they obtained, the scientists then developed a new mouse model to understand how normally beneficial immune responses were going awry.
The researchers found that immune cells known as CD8+ T cells were having faulty interactions with another type of immune cell, macrophages. These interactions were causing the macrophages to drive damaging inflammation even after the initial COVID-19 infection had resolved, when the immune system would normally stand down.
The scientists remain uncertain about the underlying trigger for the immune malfunction—the immune system may be responding to lingering remnants of the COVID-19 virus, for example, or there could be some other cause, they say.
Breaking the Cycle
The new research suggests that this harmful cycle of inflammation, injury, and fibrosis can be broken using drugs such as baricitinib and anakinra, both of which have already been approved by the US Food and Drug Administration to treat the harmful inflammation seen in rheumatoid arthritis and alopecia.
While more study is needed to verify the drugs’ effectiveness for this new purpose, the researchers hope their findings will eventually offer patients with persistent post-COVID lung problems much-needed treatment options.
“Tens of millions of people around the world are dealing with complications from long COVID or other post-infection syndromes,” Sun says in a release. “We are just beginning to understand the long-term health effects caused by acute infections. There is a strong need for more basic, translational, and clinical research, along with multi-disciplinary collaborations, to address these unmet needs of patients.”
